安徽医药
安徽醫藥
안휘의약
ANHUI MEDICAL AND PHARMACEUTICAL JOURNAL
2015年
2期
377-379
,共3页
王文平%张永明%邹永红%丁晓洁%王萍
王文平%張永明%鄒永紅%丁曉潔%王萍
왕문평%장영명%추영홍%정효길%왕평
黛力新%痛性糖尿病周围神经病变%抑郁%疗效
黛力新%痛性糖尿病週圍神經病變%抑鬱%療效
대력신%통성당뇨병주위신경병변%억욱%료효
deanxit%painful diabetic peripheral neuropathy%depression%curative effect
目的:观察黛力新治疗痛性糖尿病周围神经病变伴抑郁的临床疗效。方法将80例伴有抑郁症状的2型糖尿病痛性周围神经病变患者随机分为A组(观察组)、B组(对照组),两组均静脉给予甲钴胺及α-硫辛酸治疗2周,观察组在此基础上加用黛力新口服2周。治疗前后测空腹血糖(FPG)、餐后2 h血糖(2hPG)及糖化血红蛋白(HbA1C),行四肢运动神经传导速度( MNCV)、感觉神经传导速度( SNCV)检查、汉密尔顿抑郁量表( HAMD)评分、神经主觉症状问卷( TSS)评分、视觉模拟评分( VAS),观察药物副作用,评价临床疗效。结果治疗前两组患者FPG、2hPG、HbA1 C、MNCV、SNCV及HAMD、TSS、VAS分值均无显著性差异(P>0.05);治疗2周后与B组比较,A组MNCV、SNCV均较前改善(P<0.05);HAMD、TSS、VAS分值均较治疗前减低,差异有统计学意义(P<0.05),总有效率A组(77.5%)明显高于B组(60.0%)(P<0.05)。结论黛力新可有效改善痛性糖尿病周围神经病变的症状,同时可减轻抑郁。
目的:觀察黛力新治療痛性糖尿病週圍神經病變伴抑鬱的臨床療效。方法將80例伴有抑鬱癥狀的2型糖尿病痛性週圍神經病變患者隨機分為A組(觀察組)、B組(對照組),兩組均靜脈給予甲鈷胺及α-硫辛痠治療2週,觀察組在此基礎上加用黛力新口服2週。治療前後測空腹血糖(FPG)、餐後2 h血糖(2hPG)及糖化血紅蛋白(HbA1C),行四肢運動神經傳導速度( MNCV)、感覺神經傳導速度( SNCV)檢查、漢密爾頓抑鬱量錶( HAMD)評分、神經主覺癥狀問捲( TSS)評分、視覺模擬評分( VAS),觀察藥物副作用,評價臨床療效。結果治療前兩組患者FPG、2hPG、HbA1 C、MNCV、SNCV及HAMD、TSS、VAS分值均無顯著性差異(P>0.05);治療2週後與B組比較,A組MNCV、SNCV均較前改善(P<0.05);HAMD、TSS、VAS分值均較治療前減低,差異有統計學意義(P<0.05),總有效率A組(77.5%)明顯高于B組(60.0%)(P<0.05)。結論黛力新可有效改善痛性糖尿病週圍神經病變的癥狀,同時可減輕抑鬱。
목적:관찰대력신치료통성당뇨병주위신경병변반억욱적림상료효。방법장80례반유억욱증상적2형당뇨병통성주위신경병변환자수궤분위A조(관찰조)、B조(대조조),량조균정맥급여갑고알급α-류신산치료2주,관찰조재차기출상가용대력신구복2주。치료전후측공복혈당(FPG)、찬후2 h혈당(2hPG)급당화혈홍단백(HbA1C),행사지운동신경전도속도( MNCV)、감각신경전도속도( SNCV)검사、한밀이돈억욱량표( HAMD)평분、신경주각증상문권( TSS)평분、시각모의평분( VAS),관찰약물부작용,평개림상료효。결과치료전량조환자FPG、2hPG、HbA1 C、MNCV、SNCV급HAMD、TSS、VAS분치균무현저성차이(P>0.05);치료2주후여B조비교,A조MNCV、SNCV균교전개선(P<0.05);HAMD、TSS、VAS분치균교치료전감저,차이유통계학의의(P<0.05),총유효솔A조(77.5%)명현고우B조(60.0%)(P<0.05)。결론대력신가유효개선통성당뇨병주위신경병변적증상,동시가감경억욱。
Objective To observe the curative effect of deanxit in the treatment of painful diabetic peripheral neuropathy (PDPN). Methods 80 patients with PDPN were randomly divided into the observation group ( B group) and the control group ( A group) with 40 cases in each group.Both groups were received intravenously mecobalamin and α-lipoic acid.Moreover, B group was given deanxit orally for 2 weeks.The fasting plasma glucose (FPG), 2 hours plasma glucose (2hPG), glycosylated hemoglobin A1c ( HbA1 C) , motor nerve conduction velocity ( MNCV ) , sensory nerve conduction velocity ( SNCV ) , Hamilton Depression Scale ( HAMD) scores, total symptoms scores ( TSS) , visual analysis scale ( VAS) , drug’ s adverse effect, and clinical therapeutic effect were detected before and after treatment in both groups.Results There were no significant differences in FPG, 2hPG, HbA1 C, MNCV, SNCV, HAMD, TSS, and VAS sorces between A and B group.Compared with B group, MNCV and SNCV increased in A group (P<0.05), while HAMD, TSS and VAS scores significantly decreased (P<0.05) in A group after treatment of 2 weeks.The total effective rate of A group (77.5%) was significantly higher than that in B group (60.0%).Conclusion Deanxit can effectively relieve the clinical symptoms of PDPN, and the depression as well.